| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — |
| Current Ratio | 7.47 | 9.29 | 8.41 | 13.25 | 17.31 | 4.46 | 7.64 | 19.16 | 10.02 |
| Quick Ratio | 7.47 | 9.29 | 8.41 | 13.25 | 17.31 | 4.46 | 7.64 | 19.16 | 10.02 |
| Debt / Equity | — | — | — | — | — | — | — | — | — |
| ROE | -73.36% | -62.76% | -83.83% | -23.87% | -20.45% | -33.40% | -101.27% | -36.10% | 105.79% |
| ROA | -60.72% | -53.18% | -68.82% | -21.10% | -18.29% | -23.84% | -88.10% | -34.21% | -61.20% |
| Asset Turnover | — | — | — | — | — | — | — | — | — |
| Book Value / Share | 23.10 | 2.12 | 3.95 | 7.12 | 9.79 | 15.00 | 38.03 | 50.84 | — |
Adicet Bio, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of allogeneic gamma delta T cell therapies. These off-the-shelf treatments harness gamma delta T cells to target and eliminate cancer cells through multiple mechanisms, while also facilitating innate and adaptive immune responses, and providing B-cell depletion for immune reset in autoimmune diseases. The company's novel platform emphasizes key advantages such as precise novel targeting, effective tissue homing, optimal drug exposure, and immediate availability on demand, distinguishing it from autologous therapies. Adicet Bio, Inc. focuses on delivering first-in-class solutions for patients battling cancer and autoimmune conditions, supported by a collaborative team driving innovation in the cell therapy sector. With operations in Redwood City, California; Boston, Massachusetts; and Shanghai, China, the company advances cutting-edge science toward curative potential in oncology and immunology markets.